Dermatology-directed assessment of two-year efficacy, safety and skin findings from the EPIC-Skin Study
At the 22nd EADO Congress in Prague, OncoBeta presented a dermatology-directed analysis of the Phase IV EPIC-Skin Study. The poster highlighted two-year efficacy and safety outcomes following Rhenium-SCT® treatment for non-melanoma skin cancer, including an independent dermatology assessment of skin findings, healing trajectories and cosmetic outcomes.
View Scientific Poster: EADO 2026 Poster
View presentation: EPIC_24m_Presentation_EADO_3.pdf